Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research[1][2].
Sifalimumab (3-36 μg/well; 72 h) attenuates lymphocyte cytotoxicity co-cultured with U-87MG[2].
Cell Viability Assay[2]
| Cell Line: | U-87MG cells and AGS lymphocytes |
| Concentration: | 3-36 μg/well |
| Incubation Time: | 72 hours |
| Result: | Attenuated lymphocyte cytotoxicity triggered by IFN I (P<0.05). |
Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration[2].
| Animal Model: | Wild-type male BALB/c mice[2] |
| Dosage: | 30 mg/kg and 3 μg/g |
| Administration: | Subcutaneous injection; 30 mg/kg and 3 μg/g |
| Result: | Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05). Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration. Attenuated the CD45 increase (P<0.05). |
[1]. Merrill JT, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905-13.
[2]. La Maestra S, et al. Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation. Drug Deliv Transl Res. 2018 Oct;8(5):1345-1354.